Cystic fibrosis-related diabetes mellitus: Etiology, evaluation, and management

Endocrine Practice

Volumn 14, Issue 9, 2008, Pages 1169-1179

  Fischman, Daniel ^a,b   Nookala, Vinod K ^a  

^a Harrisburg Hospital   (United States)

^b Pinnacle Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ALPHA TOCOPHEROL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; MIGLITOL; MULTIVITAMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; RETINOL; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; VITAMIN D; VITAMIN K GROUP; ANTIDIABETIC AGENT;

BULIMIA; CALORIC INTAKE; CARBOHYDRATE DIET; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES MELLITUS; DIABETES MELLITUS; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; LIPID DIET; LUNG FUNCTION; LUNG TRANSPLANTATION; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL SUPPORT; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PANCREAS ISLET CELL; POLYDIPSIA; POLYURIA; REVIEW; VITAMIN SUPPLEMENTATION; DIET THERAPY; FEMALE; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PREVALENCE;

CYSTIC FIBROSIS; DIABETES MELLITUS; DIET THERAPY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LUNG TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREVALENCE;

EID: 64049117390     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.9.1169     Document Type: Review

References (77)

1. Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med. 2007;28: 279-288.
2. Cystic Fibrosis Foundation Patient Registry: 2006 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2007.
3. Moran A. Endocrine complications of cystic fibrosis. Adolesc Med. 2002;13:145-159, vii-viii.
4. Cystic Fibrosis Foundation Patient Registry: 2005 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2006.
5. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146:681-687.
6. Costa M, Potvin S, Hammana I, et al. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cyst Fibros. 2007;6:376-383.
7. Moran A. Diagnosis, screening, and management of cystic fibrosis-related diabetes. Curr Diab Rep. 2002;2:111-115.
8. Sims EJ, Green MW, Mehta A. Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. Diabetes Care. 2005;28:1581-1587.
9. Tofé S, Moreno JC, Máiz L, Alonso M, Escobar H, Barrio R. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur J Endocrinol. 2005;152:241-247.
10. Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet Med. 2007;24:1143-1148.
11. Rolon MA, Benali K, Munck A, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 2001;90:860-867.
12. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract. 1999;45:61-73.
13. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med. 2002;19:221-226.
14. Lombardo F, De Luca F, Rosano M, et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol. 2003;149:53-59.
15. Cucinotta D, De Luca F, Scoglio R, et al. Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year follow-up study. Acta Paediatr. 1999;88:389-393.
16. Stalvey MS, Muller C, Schatz DA, et al. Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury. Diabetes. 2006;55:1939-1945.
17. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr. 1998;133: 10-17.
18. Dobson L, Sheldon CD, Hattersley AT. Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency? J R Soc Med. 2004;97(suppl 44):26-35.
19. Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA. Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. J Pediatr. 2007;151:653-658.
20. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677-681.
21. Solomon MP, Wilson DC, Corey M, et al. Glucose intolerance in children with cystic fibrosis. J Pediatr. 2003;142: 128-132.
22. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med. 2004;21:691-696.
23. Davidson MH. Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007;99:41B-50B.
24. Unger J. Diagnosis and management of type 2 diabetes and prediabetes. Prim Care. 2007;34:731-759, vi.
25. Lee TJ, Safranek S. FPIN's clinical inquiries: A1C testing in the diagnosis of diabetes mellitus. Am Fam Physician. 2006;74:143-144.
26. Moran A. Cystic fibrosis-related diabetes: an approach to diagnosis and management. Pediatr Diabetes. 2000;1:41-48.
27. Ward SA, Tomezsko JL, Holsclaw DS, Paolone AM. Energy expenditure and substrate utilization in adults with cystic fibrosis and diabetes mellitus. Am J Clin Nutr. 1999; 69:913-919.
28. Brunzell C, Schwarzenberg SJ. Cystic fibrosis-related diabetes and abnormal glucose tolerance: overview and medical nutrition therapy. Diabetes Spectrum. 2002;15: 124-127.
29. Rafii M, Chapman K, Stewart C, et al. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. Am J Clin Nutr. 2005;81:421-426.
30. Elborn JS. How can we prevent multisystem complications of cystic fibrosis? Semin Respir Crit Care Med. 2007; 28:303-311.
31. Parrish CR. Nutrition issues in gastroenterology, series #27: nutrition issues in cystic fibrosis. Practical Gastroenterol. 2005;27:76, 78-80, 82, 84-85, 87-88, 90, 92-94.
32. Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med. 2007; 28:331-346.
33. Hankard R, Munck A, Navarro J. Nutrition and growth in cystic fibrosis. Horm Res. 2002;58(suppl 1):16-20.
34. Slesinski MJ, Gloninger MF, Costantino JP, Orenstein DM. Lipid levels in adults with cystic fibrosis [published correction appears in J Am Diet Assoc. 1994;94:1101]. J Am Diet Assoc. 1994;94:402-408.
35. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Kara - mouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr. 2001;90:515-519.
36. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child. 2002;87:430-431.
37. Spence C. Cystic fibrosis-related diabetes: practice challenges. Paediatr Nurs. 2005;17:23-26.
38. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 suppl):1S-39S.
39. Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm. 2006;63:929-938.
40. Hinds A, Sheehan AG, Parsons HG. Tolbutamide causes a modest increase in insulin secretion in cystic fibrosis patients with impaired glucose tolerance. Metabolism. 1995;44:13-18.
41. Sheppard DN, Welsh MJ. Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J Gen Physiol. 1992; 100:573-591.
42. Onady GM, Langdon LJ. Insulin versus oral agents in the management of cystic fibrosis related diabetes: a case based study. BMC Endocr Disord. 2006;6:4.
43. Rosenecker J, Eichler I, Bärmeier H, von der Hardt H. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatr Pulmonol. 2001;32:351-355.
44. Mackie AD, Thornton SJ, Edenborough FP. Cystic fibrosis-related diabetes. Diabet Med. 2003;20:425-436.
45. Battezzati A, Battezzati PM, Constantini D, et al. Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol. 2007;156:369-376.
46. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am. 1997;26:523-537.
47. Staels B. Metformin and pioglitazone: effectively treating insulin resistance. Curr Med Res Opin. 2006;22(suppl 2): S27-S37.
48. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity. Diabet Med. 1999;16:273-281.
49. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22: 925-927.
50. Kamber N, Davis WA, Bruce DG, Davis TM. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Aust. 2008;188:446-449.
51. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163:2594-2602.
52. Freedman SD, Zaman MM, Anderson C. PPARs in cystic fibrosis [abstract S4.1]. Pediatr Pulmonol. 2005;40 (suppl 28):104.
53. Beale S, Bagust A, Shearer AT, Martin A, Hulme L. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2006;24(suppl 1):21-34.
54. Leiter LA. Can thiazolidinediones delay disease progression in type 2 diabetes? Curr Med Res Opin. 2006;22: 1193-1201.
55. Nathan DM, Berkwits M. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med. 2007;146:461-463.
56. Fonseca VA, Kahn SE. Of HOPEs and DREAMs: the quest to prevent type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4762-4763.
57. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634-2643.
58. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007; 357:100]. N Engl J Med. 2007;356:2457-2471.
59. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007;153:445.e1-445.e6.
60. Rosmarakis ES, Falagas ME. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J. 2007;154:144-150.
61. Sauer WH, Cappola AR, Berlin JA, Kimmel SE. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol. 2006;97:651-654.
62. Scott T. Does pioglitazone benefit patients with type 2 diabetes? Am Fam Physician. 2007;76:969-970.
63. Wilcox R, Kupfer S, Erdmann E (PROactive Study Investigators). Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial in macro Vascular Events (PROactive 10) [published correction appears in Am Heart J. 2008;156:255]. Am Heart J. 2008;155:712-717.
64. Kentrup H, Bongers H, Spengler M, Kusenbach G, Skopnik H. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Eur J Pediatr. 1999;158:455-459.
65. Minicucci L, Lorini R, Giannattasio A, et al. Liver disease as risk factor for cystic fibrosis-related diabetes development. Acta Paediatr. 2007;96:736-739.
66. Iltz JL, Baker DE, Setter SM, Campbell RK. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther. 2006;28:652-665.
67. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
68. Whitley HP. Sitagliptin (Januvia) for the treatment of patients with type 2 diabetes. Am Fam Physician. 2007;76: 858-861.
69. Unger J. Current strategies for evaluating, monitoring, and treating type 2 diabetes mellitus. Am J Med. 2008;121(6 suppl):S3-S8.
70. Sueblinvong V, Whittaker LA. Fertility and pregnancy: common concerns of the aging cystic fibrosis population. Clin Chest Med. 2007;28:433-443.
71. Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cystic Fibrosis. 2008;7:S2-S32.
72. Hardin DS, Rice J, Cohen RC, Ellis KJ, Nick JA. The metabolic effects of pregnancy in cystic fibrosis [published correction appears in Obstet Gynecol. 2005;106:869]. Obstet Gynecol. 2005;106:367-375.
73. Metzger BE, Lowe LP, Dyer AR, et al (HAPO Study Cooperative Research Group). Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358: 1991-2002.
74. Galerneau F, Inzucchi SE. Diabetes mellitus in pregnancy. Obstet Gynecol Clin North Am. 2004;31:907-933, xixii.
75. Rowan JA, Hague WM, Gao W, et al (MiG Trial Investigators). Metformin versus insulin for the treatment of gestational diabetes [published correction appears in N Engl J Med. 2008;359:106]. N Engl J Med. 2008;358: 2003-2015.
76. Hadjiliadis D, Madil J, Chaparro C, et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin Transplant. 2005;19:773-778.
77. Fridell JA, Vianna R, Kwo PY, et al. Simultaneous liver and pancreas transplantation in patients with cystic fibrosis. Transplant Proc. 2005;37:3567-3569.